

ELECTRONIC SUPPLEMENTARY INFORMATION

Protic **onium salts**-catalyzed synthesis of 5-aryl-2-oxazolidinones from aziridines and CO₂ under mild conditions

Zhen-Zhen Yang, Yu-Nong Li, Yang-Yang Wei and Liang-Nian He*

,State Key Laboratory and Institute of Elemento-Organic Chemistry, Nankai University, Tianjin,

People's Republic of China

** Corresponding author: Tel: +86-22-23501493; Fax: +86-22-23501493; E-mail:*

heln@nankai.edu.cn

Table of Contents

	page
1. General experimental methods	2
2. General procedure for the preparation of ionic liquids	2
3. General procedure for the preparation of aziridines	2
4. General Procedure for Carboxylation of Aziridine with CO ₂	2
5. Characterization of protic onium salts	3
6. Characterization of aziridines	4
7. Characterization of oxazolidinones and piperazines	5
8. References	6
9. The ¹ H NMR and ¹³ C NMR charts for protic onium salts	7
10. The ¹ H NMR charts for aziridines	19
11. The ¹ H NMR and ¹³ C NMR Charts for oxazolidinones	24
12. The ¹ H NMR charts of dimer of 1a	37

1. General experimental methods

Caution

Experiments using compressed gases CO₂ are potentially hazardous and must only be carried out by using the appropriate equipment and under rigorous safety precautions.

Materials

Aziridines and ionic liquids were synthesized according to the published procedures.^{1, 2} CO₂ with a purity of 99.99% was commercially available. The other organic and inorganic compounds from Tianjin Guangfu Fine Chemical Research Institute were used without further purification except for the solvents, which were distilled by the known method prior to use.

Experimental methods

¹H NMR spectra was recorded at Bruker 300 or 400 spectrometer in CDCl₃ and CDCl₃ (7.26 ppm) was used as internal reference, ¹³C NMR was recorded at 75 or 100.6 MHz in CDCl₃ and CDCl₃ (77.0 ppm) was used as internal reference. ESI-MS were recorded on a Thermo Finnigan LCQ Advantage spectrometer in ESI mode with a spray voltage of 4.8 kV. GC analyses were performed on Shimadzu GC-2014, equipped with a capillary column (RTX-5, 30 m × 0.25 μm) using a flame ionization detector. Melting points were measured on an X4 apparatus and uncorrected.

2. General procedures for the preparation of protic onium salts

Protic onium salts

To a 50 mL three-necked flask was added the base (10 mmol). A solution of the corresponding acid (10 mmol) was then added dropwise at the temperature of < 5 °C cooled by ice bath. After addition, the ice bath was removed and the reaction mixture was stirred for a further 10 h and then the solvent was evaporated. The remaining solid was dried under vacuum at 60 °C for 24 h after washing by ethyl ether for three times to afford the protic onium salts.

C₄DABCOCl

A solution of freshly sublimed DABCO (0.5609 g, 5 mmol) in MeCN (5 mL) was prepared at r.t. under Ar in a flame dried round-bottomed flask equipped with a reflux condenser. The resulting clear, colorless solution was treated with 1-chlorobutane (2.5 mmol), added dropwise via syringe, and the reaction mixture was heated to 80 °C (oil bath temperature) and stirred for 22 h. After being cooled to r.t., the reaction mixture was transferred via cannula into 20 mL of Et₂O, yielding a white slurry which eventually separated into two layers. The whole was transferred to a separatory funnel, and the bottom layer was collected, washed repeatedly with Et₂O and dried under high vacuum at 60 °C for 16 h to yield 1-butyl-4-aza-1-azabicyclo[2.2.2]octane chloride as a white solid.

3. General procedure for the preparation of aziridines

Typical procedure was described as below. The bromine (32.0 g, 0.2 mol) in dry CH₂Cl₂ (40 mL) was added dropwise over 30 min to ice-cooled 40 mL CH₂Cl₂ solution of dimethyl sulfide (12.4 g, 0.2 mol). During the addition, light orange crystals of bromodimethyl sulfonium bromide began to separate. After addition of bromine, the orange crystals **S1** were collected by filtration and then washed with dry diethyl ether and dried under vacuum. Yield: 80%, Mp 80 °C (dec).

Olefin (160 mmol) was added dropwise to the 160 mL CH₃CN solution of **S1** (35.56 g, 160 mmol) in ice-water bath. During the addition, the white solid began to separate. The solution was further stirred for 10 min. The crystals **S2** was collected by filtration, dried under vacuum. Yield: 32-38.6 %.

A solution of amine (20-50 mmol) in water was added dropwise to a stirred solution of compound **S2** (10 mmol) in 20 mL of H₂O at r.t., and the resulting mixture was stirred overnight. The mixture was added into 20 mL of saturated brine, extracted with diethyl ether (3×20 mL), dried with anhydrous MgSO₄ overnight and evaporated under reduced pressure. Aziridine was obtained by distillation under reduced pressure. Yield: 85-100 %.

4. General Procedure for Carboxylation of Aziridine with CO₂

In a typical reaction, the carboxylation of aziridines with CO₂ was carried out in a 25 mL stainless steel

autoclave. Aziridine (1 mmol) and the catalyst were charged into the reactor at room temperature. CO₂ was introduced into the autoclave and then the mixture was stirred at predetermined temperature for 5 min to reach the equilibration. The pressure was then adjusted to the desired pressure and the mixture was stirred continuously. When the reaction finished, the reactor was cooled in ice-water and CO₂ was ejected slowly. An aliquot of sample was taken from the resultant mixture and dissolved in dry CH₂Cl₂ for GC analysis using a flame ionization detector. The residue was purified by column chromatography on silica gel (eluting with 8:1 to 1:1 petroleum ether/ethyl acetate) to afford the product. The products were further identified by ¹H NMR, ¹³C NMR and MS which are consistent with those reported in the literature¹ and in good agreement with the assigned structures. For the catalyst recycling process, firstly, a very small part of the resultant mixture was taken and analyzed by GC and then, substrate (**1a**, 1 mmol) for the next run was added to the residual reaction mixture. Finally, the reaction was carried out under identical reaction conditions.

5. Characterization of protic onium salts

HPyI

Light yellow solid; Mp 172-173 °C; ¹H NMR (400 MHz, D₂O) δ 8.78 (d, ³J = 6 Hz, 2 H), 8.63 (t, ³J = 8 Hz, 1 H), 8.08 (t, ³J = 6.8 Hz, 2 H); ¹³C {¹H} NMR (100.6 MHz, D₂O) δ 147.1, 141.1, 127.4; Elemental analysis calcd. (%) for C₅H₆NI: C 29.01, H 2.92, N 6.77, I 61.30, found: C 29.02, H 3.01, N 6.45.

HPyBr

Light yellow solid; Mp 146-149 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.99 (d, ³J = 4 Hz, 2 H), 8.55 (t, ³J = 7.6 Hz, 1 H), 8.08 (t, ³J = 6.8 Hz, 2 H); ¹³C {¹H} NMR (100.6 MHz, D₂O) δ 146.2, 140.9, 127.3; ESI-MS (4.8 kV): m/z (%) = 80.13 (100) [M-Br]⁺.

HPyCl

White solid; Mp 118-120 °C; ¹H NMR (400 MHz, D₂O) δ 8.78 (d, ³J = 5.6 Hz, 2 H), 8.62 (t, ³J = 7.6 Hz, 1 H), 8.07 (t, ³J = 6.8 Hz, 2 H); ¹³C {¹H} NMR (100.6 MHz, D₂O) δ 147.2, 141.0, 127.4; ESI-MS (4.8 kV): m/z (%) = 80.11 (100) [M-Cl]⁺.

HPyNO₃

White solid; Mp 110-113 °C; ¹H NMR (400 MHz, D₂O) δ 8.80 (d, ³J = 5.6 Hz, 2 H), 8.64 (t, ³J = 8 Hz, 1 H), 8.10 (t, ³J = 7.2 Hz, 2 H); ¹³C {¹H} NMR (100.6 MHz, D₂O) δ 147.1, 141.1, 127.4.

HPyHSO₄:

White solid; Mp 93-95 °C; ¹H NMR (400 MHz, D₂O) δ 8.79 (d, ³J = 5.6 Hz, 2 H), 8.64 (t, ³J = 8 Hz, 1 H), 8.09 (t, ³J = 6.8 Hz, 2 H); ¹³C {¹H} NMR (100.6 MHz, D₂O) δ 147.2, 141.1, 127.4.

HPyH₂PO₄

White solid; Mp 93-95 °C; ¹H NMR (400 MHz, D₂O) δ 8.79 (d, ³J = 5.2 Hz, 2 H), 8.64 (t, ³J = 8 Hz, 1 H), 8.09 (t, ³J = 6.4 Hz, 2 H); ¹³C {¹H} NMR (100.6 MHz, D₂O) δ 147.2, 141.1, 127.4.

HMIImCl

White solid; Mp 78-79 °C; ¹H NMR (400 MHz, D₂O) δ 8.70 (s, 1 H), 7.47 (s, 2 H), 3.95 (s, 3 H); ¹³C {¹H} NMR (100.6 MHz, D₂O) δ 135.0, 123.0, 119.5, 35.5; ESI-MS (4.8 kV): m/z (%) = 83.16 (100) [M-Cl]⁺.

HDABCOCI

White solid; Mp 207-208 °C; ¹H NMR (400 MHz, D₂O) δ 3.22 (s, 12 H); ¹³C {¹H} NMR (100.6 MHz, D₂O) δ 43.9; ESI-MS (4.8 kV): m/z (%) = 113.20 (100) [M-Cl]⁺.

C₄DABCOCI

White solid; Mp 36-37 °C; ¹H NMR (400 MHz, CDCl₃) δ 3.67 (t, ³J = 7.2 Hz, 6 H), 3.54 (t, ³J = 8.4 Hz, 2 H), 3.25 (t, ³J = 7.2 Hz, 6 H), 1.69-1.77 (m, 2 H), 1.36-1.45 (m, 2 H), 0.97 (t, ³J = 7.2 Hz, 3 H); ¹³C {¹H} NMR (100.6 MHz, CDCl₃) δ 64.3, 52.4, 45.4, 23.9, 19.7, 13.7; ESI-MS calcd for C₁₀H₂₁N₂Cl 204.74, found 169.44 [M-Cl]⁺.

HDBUCI

White solid; Mp 65-66 °C; ^1H NMR (400 MHz, D_2O) δ 3.57-3.60 (m, 2 H), 3.54 (t, $^3J = 6$ Hz, 2 H), 3.33 (t, $^3J = 5.6$ Hz, 2 H); 2.63-2.65 (m, 2 H); 2.02 (quintet, $^3J = 5.6$ Hz, 2 H) 1.69-1.74 (m, 6 H); ^{13}C { ^1H } NMR (100.6 MHz, CDCl_3) δ 165.9, 54.2, 48.5, 37.7, 31.9, 28.7, 26.5, 23.7, 19.2; HR-MS (ESI): $m/z = 135.1386$, calcd. for $\text{C}_9\text{H}_{17}\text{N}_2$ ($\text{M}-\text{Cl}^+$): 153.1383.

HTBDCI

White solid; Mp 179-180 °C; ^1H NMR (400 MHz, D_2O) δ 3.36 (t, $^3J = 6$ Hz, 4 H), 3.28 (t, $^3J = 5.6$ Hz, 4 H); 2.02 (quintet, $^3J = 6$ Hz, 4 H); ^{13}C { ^1H } NMR (100.6 MHz, D_2O) δ 151.0, 46.5, 37.8, 20.2; HR-MS (ESI): $m/z = 140.1182$, calcd. for $\text{C}_7\text{H}_{14}\text{N}_3$ ($\text{M}-\text{Cl}^+$): 140.1177.

HHMTACI

White solid; Mp 139-141 °C; ^1H NMR (400 MHz, D_2O) δ 4.75 (s, 6 H), 4.74 (s, 6 H); ^{13}C { ^1H } NMR (100.6 MHz, D_2O) δ 71.7; HR-MS (ESI): $m/z = 141.1135$, calcd. for $\text{C}_7\text{H}_{14}\text{N}_3$ ($\text{M}-\text{Cl}^+$): 141.1131, 317.1963, calcd. for $\text{C}_{12}\text{H}_{26}\text{N}_8\text{Cl}$ (2 $\text{M}-\text{Cl}^+$): 317.1971.

6. Characterization of aziridines

1-Ethyl-2-phenylaziridine

^1H NMR (400 MHz, CDCl_3) δ 1.17 (t, $^3J = 9.6$ Hz, 3H), 1.65 (d, $^2J = 8.8$ Hz, 1H), 1.89 (d, $^2J = 4.4$ Hz, 1H), 2.30 (dd, $^3J = 4.4$ Hz, $^3J = 4.8$ Hz, 1H), 2.44 (q, $^3J = 9.6$ Hz, 2H), 7.18-7.31 (m, 5H); ESI-MS calcd for $\text{C}_{10}\text{H}_{13}\text{N}$ 147.10, found 148.31 [$\text{M} + \text{H}$] $^+$.

2-(4-Chlorophenyl)-1-ethylaziridine

^1H NMR (300 MHz, CDCl_3) δ 1.18 (t, $^3J = 6.9$ Hz, 3H), 1.65 (d, $^2J = 6.6$ Hz, 1H), 1.83 (d, $^2J = 3.3$ Hz, 1H), 2.25-2.46 (m, 3H), 7.15-7.23 (m, 4H); ESI-MS calcd for $\text{C}_{10}\text{H}_{12}\text{NCl}$ 181.66, found 182.13 [$\text{M} + \text{H}$] $^+$.

1-Ethyl-2-p-tolylaziridine

^1H NMR (400 MHz, CDCl_3) δ 1.19 (t, $^3J = 7.2$ Hz, 3H), 1.62 (d, $^2J = 6.4$ Hz, 1H), 1.86 (d, $^2J = 3.2$ Hz, 1H), 2.26 (dd, $^3J = 3.6$ Hz, $^3J = 3.2$ Hz, 1H), 2.31 (s, 3H), 2.37-2.48 (m, 2H), 7.09-7.15 (m, 4H); ESI-MS calcd for $\text{C}_{11}\text{H}_{15}\text{N}$ 161.24, found 162.20 [$\text{M} + \text{H}$] $^+$.

1-Propyl-2-phenylaziridine

^1H NMR (400 MHz, CDCl_3) δ 0.95 (t, $^3J = 10.0$ Hz, 3H), 1.60-1.67 (m, 3H), 1.89 (d, $^2J = 4.0$ Hz, 1H), 2.24-2.33 (m, 2H), 2.43-2.51 (m, 1H), 7.18-7.31 (m, 5H); ESI-MS calcd for $\text{C}_{11}\text{H}_{15}\text{N}$ 161.12, found 162.28 [$\text{M} + \text{H}$] $^+$.

1-Isopropyl-2-phenylaziridine

^1H NMR (300 MHz, CDCl_3) δ 1.17 (d, $^3J = 0.9$ Hz, 3H), 1.19 (d, $^3J = 0.9$ Hz, 3H), 1.57-1.66 (m, 2H), 1.89 (d, $^2J = 3.3$ Hz, 1H), 2.34 (dd, $^3J = 3.3$ Hz, $^3J = 3.3$ Hz, 1H), 7.17-7.31 (m, 5H); ESI-MS calcd for $\text{C}_{11}\text{H}_{15}\text{N}$ 161.12, found 162.32 [$\text{M} + \text{H}$] $^+$.

1-Butyl-2-phenylaziridine

^1H NMR (300 MHz, CDCl_3) δ 0.91 (t, $^3J = 7.2$ Hz, 3H), 1.33-1.45 (m, 2H), 1.55-1.67 (m, 3H), 1.88 (d, $^2J = 3.3$ Hz, 1H), 2.27-2.36 (m, 2H), 2.45-2.54 (m, 1H), 7.17-7.31 (m, 5H); ESI-MS calcd for $\text{C}_{12}\text{H}_{17}\text{N}$ 175.14, found 176.38 [$\text{M} + \text{H}$] $^+$.

1-Isobutyl-2-phenylaziridine

^1H NMR (300 MHz, CDCl_3) δ 0.95 (d, $^3J = 6.6$ Hz, 3H), 0.98 (d, $^3J = 6.6$ Hz, 3H), 1.65 (d, $^2J = 6.3$ Hz, 1H), 1.85-1.94 (m, 2H), 2.08 (dd, $^3J = 6.3$ Hz, $^3J = 6.6$ Hz, 1H), 2.28 (q, $^3J = 3.3$ Hz, 1H), 2.44 (dd, $^3J = 7.2$ Hz, $^2J = 11.4$ Hz, 1H), 7.17-7.31 (m, 5H); ESI-MS calcd for $\text{C}_{12}\text{H}_{17}\text{N}$ 175.14, found 176.36 [$\text{M} + \text{H}$] $^+$.

1-Benzyl-2-phenylaziridine

^1H NMR (300 MHz, CDCl_3) δ 1.84 (d, $^2J = 6.3$ Hz, 1H), 1.98 (d, $^2J = 3.3$ Hz, 1H), 2.50 (q, $^3J = 3.3$ Hz, 1H), 3.65 (ABq, $^3J_{AB} = 13.8$ Hz, $\Delta\nu_{AB} = 18.8$ Hz, 2H), 7.18-7.38 (m, 10H); ESI-MS calcd for $\text{C}_{15}\text{H}_{15}\text{N}$ 209.29, found 210.13 [$\text{M} + \text{H}$] $^+$.

1-Cyclohexyl-2-phenylaziridine

^1H NMR (300 MHz, CDCl_3) δ 1.19-1.87 (m, 13H), 2.34 (dd, $^3J = 3.3$ Hz, $^3J = 3.0$ Hz, 1H), 7.17-7.27 (m, 5H);

ESI-MS calcd for C₁₄H₁₉N 201.15, found 202.37 [M + H]⁺.

1-Cyclohexyl-2-p-tolylaziridine

¹H NMR (300 MHz, CDCl₃) δ 1.19-1.85 (m, 13 H), 2.29-2.32 (m, 4 H), 7.07-7.16 (m, 4 H).

2-(4-Chlorophenyl)-1-cyclohexylaziridine

¹H NMR (300 MHz, CDCl₃) δ 1.16-1.82 (m, 13 H), 2.31 (dd, ³J = 3.3 Hz, ³J = 3.0 Hz, 1 H), 7.17-7.26 (m, 4 H).

7. Characterization of oxazolidinones and piperazines

3-Ethyl-5-phenyloxazolidin-2-one

Colorless liquid; ¹H NMR (300 MHz, CDCl₃) δ 1.17 (t, ³J = 7.2 Hz, 3H), 3.29-3.45 (m, 3H), 3.92 (t, ³J = 8.7 Hz, 1H), 5.48 (t, ³J = 7.8 Hz, 1H), 7.34-7.42 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 12.4, 38.8, 51.5, 74.2, 125.4, 128.6, 128.8, 138.8, 157.5; ESI-MS calcd for C₁₁H₁₃NO₂ 191.09, found 192.29 (M + H)⁺, 214.38 (M + Na)⁺, 405.01 (2M + Na)⁺.

3-Ethyl-4-phenyloxazolidin-2-one

Colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 1.05 (t, ³J = 7.2 Hz, 3H), 2.79-2.88 (m, 1H), 3.48-3.57 (m, 1H), 4.10 (t, ³J = 8.0 Hz, 1H), 4.62 (t, ³J = 8.8 Hz, 1H), 4.81 (t, ³J = 7.2 Hz, 1H), 7.30-7.44 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 12.1, 36.8, 59.3, 69.7, 126.9, 129.0, 129.2, 137.8, 158.1; ESI-MS calcd for C₁₁H₁₃NO₂ 191.09, found 192.29 (M + H)⁺, 214.38 (M + Na)⁺, 405.01 (2M + Na)⁺.

1, 4-Diethyl-2, 5-diphenylpiperazine

White crystals; Mp 116-119 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.91 (t, ³J = 7.2 Hz, 6H), 1.99-2.05 (m, 2H), 2.30 (t, ³J = 10.8 Hz, 2H), 2.54-2.62 (m, 2H), 3.08 (dd, ²J = 11.6 Hz, ³J = 2.4 Hz, 2H), 3.45 (dd, ³J = 2.0 Hz, ²J = 12.0 Hz, 2H), 7.29-7.43 (m, 10H). LC-MS, calcd for C₂₀H₂₆N₂ 294.21, found 295.35 (M + H)⁺.

1, 4-Diethyl-2, 3-diphenyl-piperazine

Colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 1.01 (t, ³J = 7.2 Hz, 6H), 2.17-2.26 (m, 2H), 2.33-2.26 (m, 2H), 2.65-2.69 (m, 2H), 2.95-2.99 (q, ³J = 6.0 Hz, 2H), 3.73 (s, 2H), 7.27-7.38 (m, 6H), 7.69-7.71 (d, ³J = 7.2 Hz, 4H). LC-MS, calcd for C₂₀H₂₆N₂ 294.21, found 295.31 (M + H)⁺.

3-Ethyl-5-(4-chlorophenyl)oxazolidin-2-one

White solid; ¹H NMR (400 MHz, CDCl₃) δ 1.17 (t, ³J = 7.3 Hz, 3H), 3.30-3.43 (m, 2H), 3.69-3.76 (m, 1H), 3.92 (t, ³J = 8.7 Hz, 1H), 5.44 (t, ³J = 8.0 Hz, 1H), 7.27-7.38 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 12.6, 38.9, 51.5, 73.6, 126.9, 129.1, 134.7, 137.4, 157.4; ESI-MS calcd for C₁₁H₁₂ClNO₂ 225.67, found 451.64 (2M + H)⁺.

3-Ethyl-5-p-tolyloxazolidin-2-one

White solid; ¹H NMR (400 MHz, CDCl₃) δ 1.18 (t, ³J = 7.3 Hz, 3H), 1.62 (d, ³J = 6.4 Hz, 1H), 1.87 (d, ³J = 3.2 Hz, 1H), 2.27 (dd, ³J = 6.6 Hz, ²J = 3.2 Hz, 1H), 2.31 (s, 3H), 2.36-2.48 (m, 2H), 7.09-7.15 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 12.6, 21.2, 38.9, 51.6, 74.3, 125.6, 129.5, 135.8, 138.7, 157.7; ESI-MS calcd for C₁₂H₁₅NO₂ 205.25, found 206.45 (M + H)⁺, 411.15 (2M + H)⁺.

3-Propyl-5-phenyloxazolidin-2-one

Colorless liquid; ¹H NMR (300 MHz, CDCl₃) δ 0.91 (t, ³J = 7.2 Hz, 3H), 1.52-1.61 (m, 2H), 3.18-3.31 (m, 2H), 3.40 (t, ³J = 8.0 Hz, 1H), 3.90 (t, ³J = 8.8 Hz, 1H), 5.46 (t, ³J = 8.0 Hz, 1H), 7.31-7.37 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 10.7, 20.3, 45.5, 51.8, 74.0, 125.2, 128.4, 128.5, 138.7, 157.6; ESI-MS calcd for C₁₂H₁₅NO₂ 205.11, found 206.30 (M + H)⁺, 228.30 (M + Na)⁺, 433.04 (2M + Na)⁺.

3-Isopropyl-5-phenyloxazolidin-2-one

Colorless liquid; ¹H NMR (300 MHz, CDCl₃) δ 1.16 (d, ³J = 6.8 Hz, 3H), 1.22 (d, ³J = 6.8 Hz, 3H), 3.37 (t, ³J = 8.0 Hz, 1H), 3.87 (t, ³J = 8.8 Hz, 1H), 4.13-4.23 (m, 1H), 5.48 (t, ³J = 8.0 Hz, 1H), 7.34-7.42 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 19.1, 19.6, 44.5, 47.0, 74.2, 125.1, 128.3, 128.5, 138.7, 156.7; ESI-MS calcd for C₁₂H₁₅NO₂ 205.11, found 206.29 (M + H)⁺, 433.08 (2M + Na)⁺.

3-Butyl-5-phenyloxazolidin-2-one

Colorless liquid; ¹H NMR (300 MHz, CDCl₃) δ 0.94 (t, ³J = 7.2 Hz, 3H), 1.31-1.40 (m, 2H), 1.51-1.58 (m, 2H), 3.23-3.38 (m, 2H), 3.43 (t, ³J = 8.0 Hz, 1H), 3.92 (t, ³J = 8.8 Hz, 1H), 5.49 (t, ³J = 8.0 Hz, 1H), 7.28-7.42 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 13.4, 19.5, 29.1, 43.6, 51.8, 74.1, 125.2, 128.4, 128.5, 138.7, 157.7; ESI-MS calcd for C₁₃H₁₇NO₂ 219.13, found 220.34 (M + H)⁺, 259.48 (M + K)⁺, 461.05 (2M + Na)⁺.

3-Isobutyl-5-phenyloxazolidin-2-one

White crystals; Mp 38-42 °C; ¹H NMR (300 MHz, CDCl₃) δ 0.91 (d, ³J=4.8 Hz, 3H), 0.93 (d, ³J=4.8 Hz, 3H), 1.81-1.95 (m, 1H), 3.02-3.16 (m, 2H), 3.42 (dd, ²J=8.7 Hz, ³J=7.5 Hz, 1H), 3.91 (t, ³J=8.7 Hz, 1H), 5.48 (t, ³J=8.4 Hz, 1H), 7.32-7.41 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 19.7, 19.8, 26.7, 51.6, 52.6, 74.1, 125.3, 128.5, 128.7, 138.8, 158.0; ESI-MS calcd for C₁₃H₁₇NO₂ 219.13, found 461.22 (2M + Na)⁺, 679.70 (3M + Na)⁺.

3-Benzyl-5-phenyloxazolidin-2-one

White crystals; Mp 60-64 °C; ¹H NMR (300 MHz, CDCl₃) δ 3.28 (t, ³J=8.4 Hz, 1H), 3.75 (t, ³J=8.7 Hz, 1H), 4.45 (ABq, J_{AB}=15.0 Hz, Δν_{AB}=36.0 Hz, 2H), 5.43 (t, ³J=8.1 Hz, 1H), 7.27-7.35 (m, 10H); ¹³C NMR (75 MHz, CDCl₃) δ 48.1, 51.3, 74.3, 125.3, 127.8, 127.9, 128.6, 128.7, 135.5, 138.5, 157.8; ESI-MS calcd for C₁₆H₁₅NO₂ 253.11, found 276.44(M + Na)⁺, 781.66 (3M + Na)⁺.

3-Cyclohexyl-5-phenyloxazolidin-2-one

White crystals; Mp 92-93 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.0-1.8 (m, 10H), 3.38 (t, ³J=8.4 Hz, 1H), 3.70-3.73 (m, 1H), 3.88 (t, ³J=8.7 Hz, 1H), 5.45 (t, ³J=8.4 Hz, 1H), 7.35-7.38 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 25.1, 25.2, 29.9, 30.3, 48.1, 52.4, 74.4, 125.3, 128.5, 128.7, 138.9, 157.0; ESI-MS calcd for C₁₅H₁₉NO₂ 245.14, found 246.27 (M + H)⁺, 757.70 (3M + Na)⁺.

3-Cyclohexyl-5-p-tolyloxazolidin-2-one

White crystals; Mp 89-91 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.03-1.86 (m, 10 H), 2.36 (s, 3 H), 3.38 (t, ³J = 8.0 Hz, 1 H), 3.71-3.75 (m, 1 H), 3.85 (t, ³J = 8.7 Hz, 1 H), 5.43 (t, ³J = 8.0 Hz, 1 H), 7.17-7.26 (m, 4 H); ¹³C NMR (75 MHz, CDCl₃) δ 21.1, 25.2, 25.3, 25.4, 30.1, 30.5, 48.3, 52.5, 74.5, 125.5, 129.5, 136.0, 138.6, 157.3; ESI-MS calcd for C₁₆H₂₁NO₂ 259.16, found 260.02 (M + H)⁺, 799.55 (3M + Na)⁺; HRMS: calcd for C₁₆H₂₁NO₂ (M + H)⁺ 260.1645, found 260.1652.

5-(4-Chlorophenyl)-3-cyclohexyloxazolidin-2-one



White crystals; Mp 94-96 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.05 - 1.83 (m, 10 H), 3.34 (t, ³J = 8.0 Hz, 1 H), 3.69-3.76 (m, 1 H), 3.89 (t, ³J = 8.7 Hz, 1 H), 5.44 (t, ³J = 8.0 Hz, 1 H), 7.27-7.38 (m, 4 H); ¹³C NMR (75 MHz, CDCl₃) δ 25.2, 25.3, 30.0, 30.4, 48.2, 52.6, 73.8, 126.8, 129.0, 134.5, 137.6, 156.8; APCI-MS calcd for C₁₅H₁₈ClNO₂ 279.10, found 839.62 (3M+H)⁺, 859.60 (3M+Na)⁺; HRMS: calcd for C₁₅H₁₈ClNO₂ (M + H)⁺ 280.1099, found 280.1101.

8. References :



- (a) Y. Du, Y. Wu, A.-H. Liu and L.-N. He, *J. Org. Chem.*, 2008, **73**, 4709-4712; (b) Y. Wu, L.-N. He, et. al., *Tetrahedron*, 2009, **65**, 6204-6210.
- Z.-Z. Yang, L.-N. He, C.-X. Miao and S. Chanfreau, *Adv. Synth. Catal.*, 2010, **352**, 2233-2240.

9. The ^1H NMR and ^{13}C NMR Charts for protic onium salts



HPyI: pyridin-1-ium iodide





HPyBr: pyridin-1-ium bromide





HPyCl: pyridin-1-ium chloride





HPyNO₃: pyridin-1-ium nitrate





HPyHSO₄: pyridin-1-ium bisulfate





HPyH₂PO₄: pyridin-1-ium dihydrogen phosphate





HMImCl: 1-hydro-3-methylimidazolium chloride





HDABCOCl: 1-hydro-4-aza-1-azabicyclo-[2.2.2]octane chloride





[C₄DABCO]Cl: 1-butyl-4-aza-1-azabicyclo[2.2.2]octane chloride





HDBUCl: 1,8-diazabicyclo[5.4.0]undec-7-enium chloride





HTBDCl: 1,5,7-triazabicyclo[4.4.0]dec-5-enium chloride







HHMTACl: 1,3,5,7-tetraazatricyclo[1.1.1.1.1]dec-1-anium chloride







10. The ^1H NMR charts for aziridines























11. The ^1H NMR and ^{13}C NMR Charts for oxazolidinones










































12. The ^1H NMR charts of dimer of 1a

